<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39277582</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>Impaired SUMOylation of FoxA1 promotes nonalcoholic fatty liver disease through down-regulation of Sirt6.</ArticleTitle><Pagination><StartPage>674</StartPage><MedlinePgn>674</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">674</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-024-07054-1</ELocationID><Abstract><AbstractText>Abnormal SUMOylation is implicated in non-alcoholic fatty liver disease (NAFLD) progression. Forkhead box protein A1 (FoxA1) has been shown to protect liver from steatosis, which was down-regulated in NAFLD. This study elucidated the role of FoxA1 deSUMOylation in NAFLD. NAFLD models were established in high-fat diet (HFD)-induced mice and palmitate acid (PAL)-treated hepatocytes. Hepatic steatosis was evaluated by biochemical and histological methods. Lipid droplet formation was determined by BODIPY and Oil red O staining. Target molecule levels were analyzed by RT-qPCR, Western blotting, and immunohistochemistry staining. SUMOylation of FoxA1 was determined by Ni-NTA pull-down assay and SUMOylation assay Ultra Kit. Protein interaction and ubiquitination were detected by Co-IP. Gene transcription was assessed by ChIP and dual luciferase reporter assays. Liver FoxA1 knockout mice developed severe liver steatosis, which could be ameliorated by sirtuin 6 (Sirt6) overexpression. Nutritional stresses reduced Sumo2/3-mediated FoxA1 SUMOylation at lysine residue K6, which promoted lipid droplet formation by repressing fatty acid &#946;-oxidation. Moreover, Sirt6 was a target gene of FoxA1, and Sirt6 transcription activity was restrained by deSUMOylation of FoxA1 at site K6. Furthermore, nutritional stresses-induced deSUMOylation of FoxA1 promoted the ubiquitination and degradation of FoxA1 with assistance of murine double minute 2 (Mdm2). Finally, activating FoxA1 SUMOylation delayed the progression of NAFLD in mice. DeSUMOylation of FoxA1 at K6 promotes FoxA1 degradation and then inhibits Sirt6 transcription, thereby suppressing fatty acid &#946;-oxidation and facilitating NAFLD development. Our findings suggest that FoxA1 SUMOylation activation might be a promising therapeutic strategy for NAFLD.</AbstractText><CopyrightInformation>&#169; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Department of Pediatric, Shenzhen Children's Hospital, China Medical University, Shenzhen, 518038, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Jinwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Department of Pediatric, Longgang District Maternity &amp; Child Healthcare Hospital of Shenzhen City, (Longgang Maternity and Child Institute of Shantou University Medical College), Shenzhen, 518172, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Department of Pediatric, Shenzhen Children's Hospital, China Medical University, Shenzhen, 518038, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Department of Pediatric, Shenzhen Children's Hospital, China Medical University, Shenzhen, 518038, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Dongling</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Department of Pediatric, Shenzhen Children's Hospital, China Medical University, Shenzhen, 518038, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Mingguo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2101-3989</Identifier><AffiliationInfo><Affiliation>The Department of Pediatric, Shenzhen Children's Hospital, China Medical University, Shenzhen, 518038, Guangdong Province, China. 18938690175@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Department of Pediatric, The Third People's Hospital of Longgang District Shenzhen, Shenzhen, 518112, Guangdong Province, China. 18938690175@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051541">Hepatocyte Nuclear Factor 3-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.31</RegistryNumber><NameOfSubstance UI="C501860">Sirt6 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C516592">SIRT6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496500">Foxa1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496499">FOXA1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058207" MajorTopicYN="Y">Sumoylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051541" MajorTopicYN="Y">Hepatocyte Nuclear Factor 3-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="Y">Sirtuins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="Y">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="Y">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>14</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>14</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39277582</ArticleId><ArticleId IdType="pmc">PMC11401847</ArticleId><ArticleId IdType="doi">10.1038/s41419-024-07054-1</ArticleId><ArticleId IdType="pii">10.1038/s41419-024-07054-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484&#8211;95. 10.1038/s41574-021-00507-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-021-00507-z</ArticleId><ArticleId IdType="pmc">PMC8570106</ArticleId><ArticleId IdType="pubmed">34131333</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328&#8211;57. 10.1002/hep.29367</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29367</ArticleId><ArticleId IdType="pubmed">28714183</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69:564&#8211;8. 10.1136/gutjnl-2019-318813</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-318813</ArticleId><ArticleId IdType="pubmed">31366455</ArticleId></ArticleIdList></Reference><Reference><Citation>Scorletti E, Carr RM. A new perspective on NAFLD: Focusing on lipid droplets. J Hepatol. 2022;76:934&#8211;45. 10.1016/j.jhep.2021.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.11.009</ArticleId><ArticleId IdType="pubmed">34793866</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XC. Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health. Cells. 2023;12:663. 10.3390/cells12040663</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12040663</ArticleId><ArticleId IdType="pmc">PMC9954390</ArticleId><ArticleId IdType="pubmed">36831330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou T, Tian Y, Cao Z, Zhang J, Feng T, Tao W, et al. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation. Mol Cell. 2022;82:4099&#8211;115.e9. 10.1016/j.molcel.2022.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2022.09.018</ArticleId><ArticleId IdType="pubmed">36208627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou D, Liu L, Zeng Y, Wang H, Dai D, Xu M. LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. Cell Death Discov. 2022;8:103. 10.1038/s41420-022-00889-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-022-00889-7</ArticleId><ArticleId IdType="pmc">PMC8901640</ArticleId><ArticleId IdType="pubmed">35256601</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie K, Gao Y, Chen S, Wang Z, Wang H, Tang Y, et al. Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake. Phytomedicine. 2023;111:154661. 10.1016/j.phymed.2023.154661</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2023.154661</ArticleId><ArticleId IdType="pubmed">36682299</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren I, Moeller MM, Guiggey D, Chiang A, Maloy M, Ogoke O, et al. FOXA1/2 depletion drives global reprogramming of differentiation state and metabolism in a human liver cell line and inhibits differentiation of human stem cell-derived hepatic progenitor cells. FASEB J. 2023;37:e22652. 10.1096/fj.202101506RRR</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202101506RRR</ArticleId><ArticleId IdType="pubmed">36515690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Ye M, Qie J, Ye T. FOXA1 Promotes Cell Proliferation and Suppresses Apoptosis in HCC by Directly Regulating miR-212-3p/FOXA1/AGR2 Signaling Pathway. Onco Targets Ther. 2020;13:5231&#8211;40. 10.2147/OTT.S252890</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S252890</ArticleId><ArticleId IdType="pmc">PMC7293390</ArticleId><ArticleId IdType="pubmed">32606743</ArticleId></ArticleIdList></Reference><Reference><Citation>Moya M, Benet M, Guzman C, Tolosa L, Garcia-Monzon C, Pareja E, et al. Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver. PLoS One. 2012;7:e30014. 10.1371/journal.pone.0030014</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030014</ArticleId><ArticleId IdType="pmc">PMC3253125</ArticleId><ArticleId IdType="pubmed">22238690</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman C, Benet M, Pisonero-Vaquero S, Moya M, Garcia-Mediavilla MV, Martinez-Chantar ML, et al. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARalpha; and repressed by C/EBPalpha: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim Biophys Acta. 2013;1831:803&#8211;18. 10.1016/j.bbalip.2012.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2012.12.014</ArticleId><ArticleId IdType="pubmed">23318274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, de Th&#233; H, Lallemand-Breitenbach V. Sumoylation in Physiology, Pathology and Therapy. Cells. 2022;11:814 10.3390/cells11050814</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11050814</ArticleId><ArticleId IdType="pmc">PMC8909597</ArticleId><ArticleId IdType="pubmed">35269436</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S, Lemos V, Xu P, Demagny H, Wang X, Ryu D, et al. Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease. J Clin Invest. 2017;127:583&#8211;92. 10.1172/JCI85499</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI85499</ArticleId><ArticleId IdType="pmc">PMC5272172</ArticleId><ArticleId IdType="pubmed">28094767</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dou X, Zhou WY, Ding M, Liu L, Du RQ, et al. Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk. Hepatology. 2021;74:1864&#8211;83. 10.1002/hep.31881</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31881</ArticleId><ArticleId IdType="pubmed">33934381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013;288:29252&#8211;9. 10.1074/jbc.M113.481473</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.481473</ArticleId><ArticleId IdType="pmc">PMC3795227</ArticleId><ArticleId IdType="pubmed">23974119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong X, Huang M, Kim HG, Zhang Y, Chowdhury K, Cai W, et al. SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells. Cell Mol Gastroenterol Hepatol. 2020;10:341&#8211;64. 10.1016/j.jcmgh.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2020.04.005</ArticleId><ArticleId IdType="pmc">PMC7327931</ArticleId><ArticleId IdType="pubmed">32305562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Yang M, Li P, Sit J, Wong A, Rodrigues K, et al. High-Fat Diet-Induced DeSUMOylation of E4BP4 Promotes Lipid Droplet Biogenesis and Liver Steatosis in Mice. Diabetes. 2023;72:348&#8211;61. 10.2337/db22-0332</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db22-0332</ArticleId><ArticleId IdType="pmc">PMC9935497</ArticleId><ArticleId IdType="pubmed">36508222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Bian X, Zhang C, Wu Z, Huang N, Yang J, et al. Ginkgolic acid improves bleomycin-induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation. Oxid Med Cell Longev. 2022;2022:8002566. 10.1155/2022/8002566</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/8002566</ArticleId><ArticleId IdType="pmc">PMC9192210</ArticleId><ArticleId IdType="pubmed">35707278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang IH, Kwon OK, Hao L, Park D, Chung MJ, Oh BC, et al. Deacetylation of XBP1s by sirtuin 6 confers resistance to ER stress-induced hepatic steatosis. Exp Mol Med. 2019;51:1&#8211;11. 10.1038/s12276-019-0309-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0309-0</ArticleId><ArticleId IdType="pmc">PMC6802632</ArticleId><ArticleId IdType="pubmed">31541078</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramaniyan N, Luo Y, Sun AQ, Suchy FJ. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J Biol Chem. 2013;288:13850&#8211;62. 10.1074/jbc.M112.443937</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.443937</ArticleId><ArticleId IdType="pmc">PMC3650421</ArticleId><ArticleId IdType="pubmed">23546875</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, Zhang T, Wang K, Chen Z, Yang Y, Shan B, et al. SENP1 prevents steatohepatitis by suppressing RIPK1-driven apoptosis and inflammation. Nat Commun. 2022;13:7153. 10.1038/s41467-022-34993-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34993-0</ArticleId><ArticleId IdType="pmc">PMC9681887</ArticleId><ArticleId IdType="pubmed">36414671</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Q, Wang Z, Hu K, Cao J, Dong Y, Chen Y. Melatonin Ameliorates Hepatic Ferroptosis in NAFLD by Inhibiting ER Stress via the MT2/cAMP/PKA/IRE1 Signaling Pathway. Int J Biol Sci. 2023;19:3937&#8211;50. 10.7150/ijbs.85883</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.85883</ArticleId><ArticleId IdType="pmc">PMC10411470</ArticleId><ArticleId IdType="pubmed">37564204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakane S, Hikita H, Shirai K, Myojin Y, Sasaki Y, Kudo S, et al. White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice. Cell Mol Gastroenterol Hepatol. 2021;12:1683&#8211;99. 10.1016/j.jcmgh.2021.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2021.07.008</ArticleId><ArticleId IdType="pmc">PMC8551788</ArticleId><ArticleId IdType="pubmed">34303881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, Liu W, Hu Y, Fu N. Sumoylation in liver disease. Clin Chim Acta. 2020;510:347&#8211;53. 10.1016/j.cca.2020.07.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.07.044</ArticleId><ArticleId IdType="pubmed">32710938</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbour H, Nkwe NS, Estavoyer B, Messmer C, Gushul-Leclaire M, Villot R, et al. An inventory of crosstalk between ubiquitination and other post-translational modifications in orchestrating cellular processes. iScience. 2023;26:106276. 10.1016/j.isci.2023.106276</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.106276</ArticleId><ArticleId IdType="pmc">PMC10165199</ArticleId><ArticleId IdType="pubmed">37168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutinen P, Rahkama V, Rytinki M, Palvimo JJ. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation. Mol Endocrinol. 2014;28:1719&#8211;28. 10.1210/me.2014-1035</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2014-1035</ArticleId><ArticleId IdType="pmc">PMC5414787</ArticleId><ArticleId IdType="pubmed">25127374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J. 2010;428:133&#8211;45. 10.1042/BJ20100158</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20100158</ArticleId><ArticleId IdType="pmc">PMC3310159</ArticleId><ArticleId IdType="pubmed">20462400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X, Yang Z, Zhang K, Fang D, Sun F. SUMOylation represses the transcriptional activity of the Unfolded Protein Response transducer ATF6. Biochem Biophys Res Commun. 2017;494:446&#8211;51. 10.1016/j.bbrc.2017.10.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.10.103</ArticleId><ArticleId IdType="pmc">PMC5698096</ArticleId><ArticleId IdType="pubmed">29061306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Wang R, Liu J, Zhao K, Qian X, He X, et al. SENP1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation. Int J Biol Sci. 2022;18:2186&#8211;201. 10.7150/ijbs.60594</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.60594</ArticleId><ArticleId IdType="pmc">PMC8935229</ArticleId><ArticleId IdType="pubmed">35342335</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas E, Thankan RS, Purushottamachar P, Weber DJ, Njar VCO. Targeted Degradation of Androgen Receptor by VNPP433-3beta in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation. Cancers (Basel). 2023;15:663. 10.3390/cancers15041198</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15041198</ArticleId><ArticleId IdType="pmc">PMC9954018</ArticleId><ArticleId IdType="pubmed">36831540</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W, Yang Y, Weng L, Ye Z, Ding P, Li H, et al. Hyperhomocysteinemia activates NLRP3 inflammasome to cause hepatic steatosis and insulin resistance via MDM2-mediated ubiquitination of HSF1. Int Immunopharmacol. 2023;118:110085. 10.1016/j.intimp.2023.110085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110085</ArticleId><ArticleId IdType="pubmed">37018978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Yang H, Zhou Z, Bai Y, Wang J, Wang W. Crosstalk between SUMOylation and ubiquitylation controls DNA end resection by maintaining MRE11 homeostasis on chromatin. Nat Commun. 2022;13:5133. 10.1038/s41467-022-32920-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32920-x</ArticleId><ArticleId IdType="pmc">PMC9436968</ArticleId><ArticleId IdType="pubmed">36050397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>